Literature DB >> 12210554

Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic--A focus on analogues of benztropine and rimcazole.

Amy Hauck Newman1, Santosh Kulkarni.   

Abstract

In an attempt to discover a cocaine-abuse pharmacotherapeutic, extensive investigation has been directed toward elucidating the molecular mechanisms underlying the reinforcing effects of this psychostimulant drug. The results of these studies have been consistent with the inhibition of dopamine uptake, at the dopamine transporter (DAT), which results in a rapid and excessive accumulation of extracellular dopamine in the synapse as being the mechanism primarily responsible for the locomotor stimulant actions of cocaine. Nevertheless, investigation of the serotonin (SERT) and norepinephrine (NET) transporters, as well as other receptor systems, with which cocaine either directly or indirectly interacts, has suggested that the DAT is not solely responsible for the reinforcing effects of cocaine. In an attempt to further elucidate the roles of these systems in the reinforcing effects of cocaine, selective molecular probes, in the form of drug molecules, have been designed, synthesized, and characterized. Many of these compounds bind potently and selectively to the DAT, block dopamine reuptake, and are behaviorally cocaine-like in animal models of psychostimulant abuse. However, there have been exceptions noted in several classes of dopamine uptake inhibitors that demonstrate behavioral profiles that are distinctive from cocaine. Structure-activity relationships between chemically diverse dopamine uptake inhibitors have suggested that different binding interactions, at the molecular level on the DAT, as well as divergent actions at the other monoamine transporters may be related to the differing pharmacological actions of these compounds, in vivo. These studies suggest that novel dopamine uptake inhibitors, which are structurally and pharmacologically distinct from cocaine, may be developed as potential cocaine-abuse therapeutics. Copyright 2002 Wiley Periodicals, Inc. Med Res Rev, 22, No. 5, 429-464, 2002; Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/med.10014

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210554     DOI: 10.1002/med.10014

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  31 in total

Review 1.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

2.  Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands.

Authors:  Guangrong Zheng; Linda P Dwoskin; Agripina G Deaciuc; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2005-10-15       Impact factor: 2.823

3.  The Novel Modafinil Analog, JJC8-016, as a Potential Cocaine Abuse Pharmacotherapeutic.

Authors:  Hai-Ying Zhang; Guo-Hua Bi; Hong-Ju Yang; Yi He; Gilbert Xue; Jiajing Cao; Gianluigi Tanda; Eliot L Gardner; Amy Hauck Newman; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2017-03-07       Impact factor: 7.853

4.  Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.

Authors:  Stephen J Kohut; Takato Hiranita; Soo-Kyung Hong; Aaron L Ebbs; Valeria Tronci; Jennifer Green; Linda Garcés-Ramírez; Lauren E Chun; Maddalena Mereu; Amy H Newman; Jonathan L Katz; Gianluigi Tanda
Journal:  Biol Psychiatry       Date:  2014-04-19       Impact factor: 13.382

5.  Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters.

Authors:  Dilip K Tosh; Aaron Janowsky; Amy J Eshleman; Eugene Warnick; Zhan-Guo Gao; Zhoumou Chen; Elizabeth Gizewski; John A Auchampach; Daniela Salvemini; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2017-03-20       Impact factor: 7.446

6.  Atypical dopamine transporter inhibitors R-modafinil and JHW 007 differentially affect D2 autoreceptor neurotransmission and the firing rate of midbrain dopamine neurons.

Authors:  Alicia J Avelar; Jianjing Cao; Amy Hauck Newman; Michael J Beckstead
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 7.  Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse.

Authors:  F Ivy Carroll; James L Howard; Leonard L Howell; Barbara S Fox; Michael J Kuhar
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

8.  Chlorophenylpiperazine analogues as high affinity dopamine transporter ligands.

Authors:  William C Motel; Jason R Healy; Eddy Viard; Buddy Pouw; Kelly Martin; Rae R Matsumoto; Andrew Coop
Journal:  Bioorg Med Chem Lett       Date:  2013-10-15       Impact factor: 2.823

9.  Synthesis of 8-thiabicyclo[3.2.1]octanes and their binding affinity for the dopamine and serotonin transporters.

Authors:  Duy-Phong Pham-Huu; Jeffrey R Deschamps; Shanghao Liu; Bertha K Madras; Peter C Meltzer
Journal:  Bioorg Med Chem       Date:  2006-10-27       Impact factor: 3.641

10.  The binding sites for cocaine and dopamine in the dopamine transporter overlap.

Authors:  Thijs Beuming; Julie Kniazeff; Marianne L Bergmann; Lei Shi; Luis Gracia; Klaudia Raniszewska; Amy Hauck Newman; Jonathan A Javitch; Harel Weinstein; Ulrik Gether; Claus J Loland
Journal:  Nat Neurosci       Date:  2008-06-22       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.